White & Case has entered appearances for Gilead in Staley v. Gilead Sciences, while Arnold & Porter Kaye Scholer is representing Bristol-Myers Squibb; Drinker Biddle Reath represents Johnson & Johnson; and Holland & Knight reps Japan Tobacco.
Staley alleges that Gilead and the other drug companies have inflated the price of HIV medication through collusive licensing agreements, such as by combining Gilead compounds whose patents are expiring with other companies’ more recently patented compounds into fixed-dose combinations. The strategy is “crippling this nation’s ability to stop new HIV infections,” the plaintiffs contend in a May 14 complaint.
Gilead has said that it enters into partnerships with other companies to create life-saving therapies. “Any suggestion that we had improper motives is absolutely false,” the company has said.
Full Content: Law
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
